Education
About Us
Working with TipRanks
Follow Us
Oculis Holding (OCS)
NASDAQ:OCS
OCS Stock Chart & Stats
$22.03
$0.20(1.10%)
At close: 4:00 PM EST
$22.03
$0.20(1.10%)
Day’s Range― - ―
52-Week Range$14.00 - $23.08
Previous CloseN/A
Volume95.89K
Average Volume (3M)58.01K
Market Cap
$1.26B
Enterprise Value$692.23M
Total Cash (Recent Filing)$46.44M
Total Debt (Recent Filing)$2.47M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Mar 03, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding57,169,476
10 Day Avg. Volume127,612
30 Day Avg. Volume58,014
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)8.50
Price to Sales (P/S)908.96
P/FCF Ratio-13.06
Enterprise Value/Market Cap0.55
Enterprise Value/Revenue1.37K
Enterprise Value/Gross Profit-48.05
Enterprise Value/Ebitda-6.72
Forecast
1Y Price Target
$40.00Price Target Upside81.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Late-stage Enrollment For DME TherapyCompletion of enrollment in the Phase 3 DIAMOND program for OCS-01 eye drops positions the program to generate pivotal data that could support a regulatory submission and create a topical alternative for diabetic macular edema.
Pivotal Trial ReplicationPhase 2 ACUITY demonstrated meaningful vision and anatomical improvements versus steroid, and the PIONEER registrational trials replicate that protocol across broader populations, increasing the likelihood of confirming efficacy.
Regulatory DesignationFDA Breakthrough Therapy designation for privosegtor enables closer regulatory dialogue and expedited review mechanisms that could accelerate approval if pivotal trials confirm benefit.
Bears Say
Cash RunwayCurrent high cash burn and a limited cash runway create material funding needs that could pressure the company's ability to execute late-stage programs without external capital.
Execution RiskSustained annual cash burn elevates execution risk for ongoing trials, increasing the chance that timelines or trial scope may be altered if funding becomes constrained.
Financing And Dilution RiskUpcoming pivotal trial readouts are binary catalysts that could necessitate dilutive financing or strategic partnerships if results do not sufficiently de-risk near-term funding requirements.
Oculis Holding News
OCS FAQ
What was Oculis Holding’s price range in the past 12 months?
Oculis Holding lowest stock price was $14.00 and its highest was $23.08 in the past 12 months.
What is Oculis Holding’s market cap?
Oculis Holding’s market cap is $1.26B.
When is Oculis Holding’s upcoming earnings report date?
Oculis Holding’s upcoming earnings report date is Mar 03, 2026 which is in 52 days.
How were Oculis Holding’s earnings last quarter?
Oculis Holding released its earnings results on Nov 10, 2025. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.518 by $0.119.
Is Oculis Holding overvalued?
According to Wall Street analysts Oculis Holding’s price is currently Undervalued.
Does Oculis Holding pay dividends?
Oculis Holding does not currently pay dividends.
What is Oculis Holding’s EPS estimate?
Oculis Holding’s EPS estimate is -0.51.
How many shares outstanding does Oculis Holding have?
Oculis Holding has 57,169,476 shares outstanding.
What happened to Oculis Holding’s price movement after its last earnings report?
Oculis Holding reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.518. Following the earnings report the stock price went down -0.103%.
Which hedge fund is a major shareholder of Oculis Holding?
Currently, no hedge funds are holding shares in OCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oculis Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.00 (81.57% Upside)
$40.00 (81.57% Upside)
Hedge Fund Trend
Increased
By 33.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 79.1%
Last 30 Days ▲ 100.7%
Last 30 Days ▲ 100.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.49%
12-Months-Change
Fundamentals
Return on Equity
-80.98%
Trailing 12-Months
Asset Growth
47.79%
Trailing 12-Months
Company Description
Oculis Holding
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
OCS Stock 12 Month Forecast
Average Price Target
$40.00
▲(81.57% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Spyre Therapeutics
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Upstream Bio, Inc.
―
Ownership Overview
―
Insiders
0.38% Mutual Funds
16.54% Other Institutional Investors
82.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---